Boston Scientific Corporation BSX
- Market cap
- $64.7B
- P/E
- 17.7×
Follow BSX
Boston Scientific Corporation (BSX) EV/EBITDA
As of 25 September 2026, Boston Scientific Corporation (BSX) trades at a EV/EBITDA of 13.8×. Over the past ten years it has ranged from 0.0× (September 2016) to 470× (September 2016); the current reading is higher than 15% of that period. That is above the Medical Devices industry median of 11.8× and above the Healthcare sector median of 10.4×.
EV/EBITDA, daily
Annual
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 30.0× | (9.94%) |
| FY2024 | 33.3× | 29.72% |
| FY2023 | 25.7× | 1.30% |
| FY2022 | 25.3× | (0.25%) |
| FY2021 | 25.4× | (31.37%) |
| FY2020 | 37.0× | (22.82%) |
| FY2019 | 47.9× | 29.57% |
| FY2018 | 37.0× | 18.66% |
| FY2017 | 31.2× | (60.17%) |
| FY2016 | 78.3× | — |
Quarterly
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 13.5× | (31.52%) |
| Mar 2026 | 19.7× | (34.43%) |
| Dec 2025 | 30.0× | (3.82%) |
| Sep 2025 | 31.2× | (15.25%) |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PHG Koninklijke Philips N.V. compare | 8.6× |
| GEHC GE HealthCare Technologies Inc. compare | 11.9× |
| STE STERIS plc compare | 13.4× |
| MDT Medtronic PLC compare | 13.7× |
| BSX Boston Scientific Corporation | 13.8× |
| SYK Stryker Corporation compare | 17.2× |
| ABT Abbott Laboratories compare | 18.8× |
| DXCM DexCom, Inc. compare | 23.2× |
| EW Edwards Lifesciences Corporation compare | 28.6× |
| Medical Devices industry median | 11.8× |
| Healthcare sector median | 10.4× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on BSX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement